CW April 2005

category image Volume 14
Issue Number 4
April 2005
ISSN 10593802

Tyrosine Kinase Inhibitor Cocktails May Target Resistance to Gleevec

A cocktail of Bcr-Abl kinase inhibitors may be the best way to target the widest range of drug resistance to treatment with imatinib (Gleevec). Another experimental drug, BMS-354825, which also inhibits another tyrosine kinase, Src, shows early promise for the treatment of chronic myeloid leukemia (CML), and possibly solid tumors.
Go to Previous Page
Go to Next Page

Source & Additional Reading

Thomas O?Hare, Research Specialist at the Oregon Health & Science Cancer Institute.
Feng Luo, Senior Research Investigator, Experimental Therapeutics, at Bristol-Myers Squibb.
December 2004 at the American Society of Hematology annual meeting.

Report from the American Association of Cancer Research annual meeting.

Purchase Downloadable Full-text PDF of Article: $10.00

Subscription is more cost effective than purchasing PDFs on-the-fly.  Click here for details.

Download Complete Issue CW April 2005

Purchase Downloadable Full-text PDF of Complete Issue: $20.00

Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us

Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA
phone: 518-456-0784; fax: 518-452-4955; email: info@adeninepress.com
copyright © Adeninepress, All rights reserved.




Re-initialize IP-based Login

Mountain Media ecommerce solutions Ecommerce Solutions by Mountain Media